## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.9% in lower entry zone (3.0-6.0%), top quartile (78th pct) cross-sectional ranking. Short-term MRS_5 (3.0%) confirms momentum alignment. Strong momentum (+4.4% 5-day acceleration). Outperforming sector by 2.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($197.77)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Becton, Dickinson and Company to effect additional $10M share repurchase program**
- Source: MSN | 20260105T000804 | Somewhat-Bullish | Relevance: 100%
- Becton, Dickinson and Company (BDX) has announced an additional share repurchase program, authorizing the company to buy back up to $10 million in common stock. This new authorization follows a previously expired $10 million program and reflects the company's strategy to return capital to shareholders. The company plans to execute these repurchases through open market or privately negotiated transactions.

**2. Becton Dickinson & Co - On Dec 30, Bd 401(K) Plan to Enter Blackout Period Due to Waters Deal - SEC Filing**
- Source: TradingView â€” Track All Markets | 20260106T220740 | Somewhat-Bearish | Relevance: 100%
- Becton Dickinson & Co (BDX) announced via an SEC filing that its 401(k) plan will enter a blackout period starting December 30, related to a deal with Waters. This news item provides only the headline and states there is no additional text available.

**3. Gries Financial LLC Has $2.52 Million Stake in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20260106T121443 | Somewhat-Bullish | Relevance: 100%
- Gries Financial LLC significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 75.9% in Q3, now owning 13,484 shares valued at $2.52 million. This move comes as other institutional investors have also adjusted their positions in the medical instruments supplier. Analysts currently have a consensus "Hold" rating on BDX, with an average price target of $207.18, and the company recently raised its quarterly dividend to $1.05 per share.

**4. Mcdaniel Terry & Co. Sells 74,357 Shares of Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20260106T115457 | Neutral | Relevance: 100%
- Mcdaniel Terry & Co. significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 85.3%, selling 74,357 shares and retaining 12,841 shares valued at approximately $2.403 million. Other hedge funds made adjustments to their holdings, with some increasing and others decreasing their positions. The company recently increased its quarterly dividend to $1.05 per share, and analysts currently have a consensus "Hold" rating with a price target of $207.18 for BDX.

**5. Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $207.00 at Bank of America**
- Source: MarketBeat | 20260105T134557 | Somewhat-Bullish | Relevance: 100%
- Bank of America has increased its price target for Becton, Dickinson and Company (NYSE:BDX) shares to $207.00 from $190.00, while maintaining a "neutral" rating. This new target implies a potential upside of 6.3% from the stock's previous closing price. The consensus among analysts remains a "Hold" rating with an average target price of $207.18.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | B of A Securiti | $207 | $190 | +9% |
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-17 | RBC Capital | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 12 ($0.04M) |
| Sells | 8 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Forward P/E 12.9x stretched relative to 6% growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +6%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $58.6B |
| Beta | 0.26 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.9 |
| Current P/E | 13.7 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.5% to 3.9% (+4.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 78th percentile. MRS_5 at 3.0% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.88% (CS: 78) | Strong |
| RSI_14 | 69.1 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.091x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $205.37
- **Stop Loss:** $197.77 (3.7% risk)
- **Target:** $216.77 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 173
- **Position Value:** $35,529.01
- **Portfolio %:** 35.53%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*